Weiss Ratings Reiterates "Sell (D-)" Rating for Nanobiotix (NASDAQ:NBTX)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Nanobiotix (NASDAQ:NBTX), indicating caution for investors considering the stock.
• Nanobiotix currently holds an average rating of "Hold" from analysts, with a consensus price target of $11.00.
• A recent acquisition by Millennium Management LLC added 13,452 shares of Nanobiotix, emphasizing the interest from hedge funds which collectively own 38.81% of the company's stock.

Nanobiotix (NASDAQ:NBTX - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts also recently issued reports on the company. Leerink Partners set a $14.00 price target on Nanobiotix in a research report on Thursday, September 18th. HC Wainwright restated a "buy" rating on shares of Nanobiotix in a research report on Friday, September 19th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Nanobiotix presently has an average rating of "Hold" and a consensus price target of $11.00.

Nanobiotix Stock Performance

Shares of NBTX opened at $27.30 on Wednesday. The business has a fifty day moving average of $11.29 and a 200 day moving average of $6.66. Nanobiotix has a 52-week low of $2.76 and a 52-week high of $27.77.

Hedge Funds Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,452 shares of the company's stock, valued at approximately $39,000. Hedge funds and other institutional investors own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.